FDA approves Sorrento's post-shingles pain patch

Scilex Pharmaceuticals Inc. (San Diego, Calif.), a majority-owned subsidiary of Sorrento Therapeutics Inc. (NASDAQ:SRNE), said FDA approved ZTlido 1.8% lidocaine patch to treat pain associated with postherpetic neuralgia (PHN).

Sorrento said Scilex will launch ZTlido this year. The company did not respond to inquiries about the therapy's price and launch date...